Recon Regulatory ZKR Orthopedics Announces First Patella LIFT™ Surgeries on the East Coast at Hospital for Special Surgery in Enrollment of FDA PELICAN Trial byJosh SandbergSeptember 16, 2025
Spine ReGelTec Announces First Patient Treated in U.S. IDE Clinical Trial for HYDRAFIL System to Treat Chronic Low Back Pain byJosh SandbergJune 18, 2025
Recon Regulatory Sports Medicine Hyalex Orthopaedics Receives FDA Approval of IDE Supplement, Expanding the Early Feasibility Study to a Pivotal Trial of Cutting-Edge Freestyle Knee Implant byTim AllenMay 20, 2025
Spine Top Stories Interim Analysis Of 2-Level BAGUERA® C IDE Study Meets Threshold For Non-Inferiority byTim AllenApril 16, 2025
Recon Top Stories JointMedica Announces Launch of IDE Study for Polymotion® Hip Resurfacing System byJosh SandbergApril 1, 2025
Spine Interim analysis of 1-level BAGUERA®C IDE study meets threshold for non-inferiority byJosh SandbergMarch 11, 2025
Regulatory Lipogems Announces Enrollment of the Final Patient in ARISE FDA Clinical Trials for Knee Osteoarthritis byJosh SandbergMarch 5, 2025
Recon Regulatory Top Stories Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis byTim AllenApril 10, 2024
Recon Regulatory Top Stories Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis byTim AllenApril 8, 2024
Biologics Regulatory U.S. FDA Grants Lipogems® Second IDE Approval For A Clinical Trial On The Treatment For Knee OA byJosh SandbergOctober 4, 2023
